These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34473839)

  • 1. Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
    Buján Bonino C; Moreiras Arias N; López-Pardo Rico M; Pita da Veiga Seijo G; Rosón López E; Suárez Peñaranda JM; Sánchez-Aguilar Rojas D
    Int J Dermatol; 2021 Nov; 60(11):e466-e467. PubMed ID: 34473839
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine.
    de Las Vecillas L; López J; Morchón E; Rodriguez F; Drake M; Martino M
    J Investig Allergol Clin Immunol; 2021 Feb; 32(1):77-78. PubMed ID: 34588156
    [No Abstract]   [Full Text] [Related]  

  • 3. Pfizer-BioNTech SARS-CoV-2 mRNA vaccine-associated erythema multiforme.
    Borg L; Mercieca L; Mintoff D; Micallef D; Pisani D; Betts A; Scerri L
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e22-e24. PubMed ID: 34547125
    [No Abstract]   [Full Text] [Related]  

  • 4. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
    Lavery MJ; Nawimana S; Parslew R; Stewart L
    Clin Exp Dermatol; 2021 Oct; 46(7):1325-1327. PubMed ID: 33914926
    [No Abstract]   [Full Text] [Related]  

  • 5. Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech).
    Kim MJ; Kim JW; Kim MS; Choi SY; Na JI
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e98-e100. PubMed ID: 34661942
    [No Abstract]   [Full Text] [Related]  

  • 6. [Erythema multiforme following COVID-19 vaccination (BNT162b2)].
    Wunderlich K; Dirschka T
    Hautarzt; 2022 Jan; 73(1):68-70. PubMed ID: 34676438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.
    Petruzzi M; Galleggiante S; Messina S; Della Vella F
    BMC Oral Health; 2022 Mar; 22(1):90. PubMed ID: 35331228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine.
    Tano E; San Martin S; Girgis S; Martinez-Fernandez Y; Sanchez Vegas C
    J Pediatric Infect Dis Soc; 2021 Nov; 10(10):962-966. PubMed ID: 34319393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythema Multiforme Induced by Zonisamide and Triggered by the First Dose of COVID-19 Vaccine (Pfizer-BioNTech).
    Murata T; Nobukuni Y
    Am J Ther; 2023 May; 30(3):e261-e265. PubMed ID: 37278706
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythema multiforme after SARS-CoV-2 vaccine.
    Zhang LW; Wang WJ; Li CH; Chen T
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e32-e33. PubMed ID: 34547118
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
    Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
    PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Unusual Presentation of Erythema Multiforme Following the Administration of Pfizer-BioNTech COVID-19 mRNA Vaccine in a Pediatric Patient.
    Alghamdi Y; Abdulghani F; Huwait HF; Abdulghani M; Samarkandy SJ
    Cureus; 2024 Apr; 16(4):e58450. PubMed ID: 38765345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.
    Gambichler T; Scholl L; Dickel H; Ocker L; Stranzenbach R
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e415-e416. PubMed ID: 33725406
    [No Abstract]   [Full Text] [Related]  

  • 15. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 17. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
    Abu-Raddad LJ; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34050372
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
    Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
    JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
    Woodworth KR; Moulia D; Collins JP; Hadler SC; Jones JM; Reddy SC; Chamberland M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Mbaeyi S; Dooling K; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(45):1579-1583. PubMed ID: 34758012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.